Still trying to dig into this but if you scroll down on the below page, the comparisons suggest to me that other trials are targeting a key symptom whereas NEU reads broader ‘PWS Behaviours’. Note I am not a scientist but this may have something to do with it, more symptoms more safety considerations?
https://www.fpwr.org/pws-clinical-trials#trials
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-111
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
-0.220(1.41%) |
Mkt cap ! $1.991B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.37 | $2.898M | 185.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 31 | $15.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 156 | 6 |
View Market Depth
| Last trade - 12.43pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |